<DOC>
	<DOCNO>NCT00345501</DOCNO>
	<brief_summary>The prevention contrast-mediated nephropathy ( CMN ) , account considerable morbidity mortality , remain vex problem . Contrast induce renal vasoconstriction believe play pivotal role CMN mechanism . The aim study examine efficacy prostacyclin analogue iloprost ( dose 1ng/kg/min ) prevent CMN high-risk patient undergo coronary procedure .</brief_summary>
	<brief_title>Iloprost Prevention Contrast-Mediated Nephropathy High-Risk Patients Undergoing Coronary Angiography and/or Intervention</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>Patients undergo clinically drive , nonemergent coronary angiography intervention institution eligible inclusion serum creatinine concentration ≥1.4 mg/dl ( 124 μmol/l ) and/or creatinine clearance &lt; 60 ml/min recent sample drawn within 1 month plan procedure Circulatory shock reason , systolic blood pressure &lt; 95 mm Hg Known acute renal failure Endstage renal disease require dialysis Intravascular administration contrast medium within previous 10 day Anticipated readministration contrast medium within follow 6 day Inability administer intravenous hydration least 4 h procedure study medication least 30 min procedure Primary intervention acute infarction ST elevation A procedure perform within 2 h acute hospital admission</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>contrast medium</keyword>
	<keyword>contrast nephropathy</keyword>
</DOC>